Skip to main navigation
Skip to search
Skip to main content
University of Eastern Piedmont Home
Italiano
English
Search content at University of Eastern Piedmont
Home
Profiles
Research units
Equipment
Projects
Research output
Genetics of Follicular Lymphoma Transformation
Laura Pasqualucci
, Hossein Khiabanian
, Marco Fangazio
, Mansi Vasishtha
, Monica Messina
, Antony B. Holmes
, Peter Ouillette
, Vladimir Trifonov
, Davide Rossi
, Fabrizio Tabbò
, Maurilio Ponzoni
, Amy Chadburn
, Vundavalli V. Murty
, Govind Bhagat
,
Gianluca Gaidano
, Giorgio Inghirami
, Sami N. Malek
, Raul Rabadan
, Riccardo Dalla-Favera
Department of Translational Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Genetics of Follicular Lymphoma Transformation'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Lymphomagenesis
100%
Follicular Lymphoma
100%
Malignancy
33%
Tumor Protein p53 (TP53)
33%
Diffuse Large B-cell Lymphoma (DLBCL)
33%
Cell Cycle Progression
33%
Germinal Center B Cells
33%
Genetic Events
33%
Copy number Analysis
33%
De Novo Diffuse Large B-cell Lymphoma
33%
Modifier Genes
33%
DNA Damage Response
33%
Genetic Profile
33%
Prognostic Implications
33%
Therapeutic Implications
33%
Whole Exome Sequencing
33%
Somatic Hypermutation
33%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
33%
Histologic Transformation
33%
Apoptotic Genes
33%
Indolent Disease
33%
Transformed Follicular Lymphoma
33%
Divergent Evolution
33%
Epigenetic Modifiers
33%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Genetics
100%
Precursor
66%
Copy Number Analysis
33%
DNA Damage Response
33%
Epigenetics
33%
Somatic Hypermutation
33%
Cell Cycle Progression
33%
Exome Sequencing
33%
Genomics
33%
Cyclin Dependent Kinase Inhibitor 2A
33%
Medicine and Dentistry
Follicular Lymphoma
100%
Diffuse Large B-Cell Lymphoma
50%
Precursor
50%
Cell Cycle Progression
25%
B Cell
25%
Germinal Center
25%
Cancer
25%
Antiapoptotic
25%
Exome Sequencing
25%
Somatic Hypermutation
25%
DNA Damage Response
25%
Cyclin Dependent Kinase Inhibitor 2A
25%
Diseases
25%